Evidence map›Paper›PMID 35251918›Full record

ArticleActa pharmaceutica Sinica. B2022

Suppressing fatty acid synthase by type I interferon and chemical inhibitors as a broad spectrum anti-viral strategy against SARS-CoV-2.

Saba R Aliyari, Amir Ali Ghaffari, Olivier Pernet, Kislay Parvatiyar, Yao Wang, Hoda Gerami, Ann-Jay Tong, Laurent Vergnes, Armin Takallou, Adel Zhang and 8 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Acta pharmaceutica Sinica. B, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
2.2field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 32 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 3 institutions in 1 country.

Saba R AliyariDepartment of Microbiology, Immunology and Molecular Genetics, University of California, Los Angeles, CA 90095, USA.
Amir Ali GhaffariDepartment of Microbiology, Immunology and Molecular Genetics, University of California, Los Angeles, CA 90095, USA.
Olivier PernetDepartment of Microbiology, Immunology and Molecular Genetics, University of California, Los Angeles, CA 90095, USA.
Kislay ParvatiyarDepartment of Microbiology, Immunology and Molecular Genetics, University of California, Los Angeles, CA 90095, USA.
Yao WangDepartment of Microbiology, Immunology and Molecular Genetics, University of California, Los Angeles, CA 90095, USA.
Hoda GeramiDepartment of Microbiology, Immunology and Molecular Genetics, University of California, Los Angeles, CA 90095, USA.
Ann-Jay TongDepartment of Microbiology, Immunology and Molecular Genetics, University of California, Los Angeles, CA 90095, USA.
Laurent VergnesDepartment of Human Genetics, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA.
Armin TakallouDepartment of Microbiology, Immunology and Molecular Genetics, University of California, Los Angeles, CA 90095, USA.
Adel ZhangDepartment of Microbiology, Immunology and Molecular Genetics, University of California, Los Angeles, CA 90095, USA.
Xiaochao WeiDivision of Endocrinology, Metabolism and Lipid Research, Washington University School of Medicine, St. Louis, MO 63110, USA.
Linda D ChilinCenter for Infectious Disease Research, School of Systems Biology, George Mason University Manassas, VA 20110, USA.
Yuntao WuCenter for Infectious Disease Research, School of Systems Biology, George Mason University Manassas, VA 20110, USA.
Clay F SemenkovichDivision of Endocrinology, Metabolism and Lipid Research, Washington University School of Medicine, St. Louis, MO 63110, USA.
Karen ReueDepartment of Human Genetics, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA.
Stephen T SmaleDepartment of Microbiology, Immunology and Molecular Genetics, University of California, Los Angeles, CA 90095, USA.
Benhur LeeDepartment of Microbiology, Immunology and Molecular Genetics, University of California, Los Angeles, CA 90095, USA.
Genhong ChengDepartment of Microbiology, Immunology and Molecular Genetics, University of California, Los Angeles, CA 90095, USA.
University of California, Los Angeles · USGeorge Mason University · USWashington University in St. Louis · US

Funding

Viral Mediated Type I Interferon InductionR01AI069120 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI CHENG, GENHONG · 2006 to 2021
$6.0M
Genetic evolution, pathogenesis and immune responses in mother to child transmission of ZIKVR01AI140718 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI CHENG, GENHONG, JUNG, JAE U · 2018 to 2022
$3.8M
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infectionR01AI158154 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI JUNG, MICHAEL E · 2020 to 2025
$1.9M
NIAID NIH HHS R01 AI069120NIAID NIH HHS R01 AI140718NIAID NIH HHS R01 AI158154
6 · The paper itself

Abstract

SARS-CoV-2 is an emerging viral pathogen and a major global public health challenge since December of 2019, with limited effective treatments throughout the pandemic. As part of the innate immune response to viral infection, type I interferons (IFN-I) trigger a signaling cascade that culminates in the activation of hundreds of genes, known as interferon stimulated genes (ISGs), that collectively foster an antiviral state. We report here the identification of a group of type I interferon suppressed genes, including fatty acid synthase (FASN), which are involved in lipid metabolism. Overexpression of FASN or the addition of its downstream product, palmitate, increased viral infection while knockout or knockdown of FASN reduced infection. More importantly, pharmacological inhibitors of FASN effectively blocked infections with a broad range of viruses, including SARS-CoV-2 and its variants of concern. Thus, our studies not only suggest that downregulation of metabolic genes may present an antiviral strategy by type I interferon, but they also introduce the potential for FASN inhibitors to have a therapeutic application in combating emerging infectious diseases such as COVID-19.

Indexed as

C75CeruleninCOVID-19FASNFatty acid synthaseIFN-ISARS-CoV-2TVB-3166

Identifiers

PMID35251918
PMCPMC8883762
OpenAlexW4214893999

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.